8-K
filed September 28, 2023, 7:59 PM ET
ticker KALV
CIK 0001348911
other material
confidence high
sentiment neutral
materiality 0.30
KalVista stockholders approve officer exculpation amendment, elect directors
KalVista Pharmaceuticals, Inc.
- Approved certificate of amendment to limit officer liability under Delaware law (20.2M for, 2.5M against).
- Elected Patrick Treanor and Edward W. Unkart as Class II directors for three-year terms.
- Ratified Deloitte & Touche as independent auditor for FY ending April 30, 2024 (30.8M for, 1.6K against).
- Non-binding advisory vote on named executive officer compensation passed (20.0M for, 2.7M against).
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
KalVista Pharmaceuticals, Inc.: Certificate of amendment to certificate of incorporation to permit exculpation of certain officers from liability in specific circumstances (effective 2023-09-26).
- Change
- charter amendment
- Effective
- 2023-09-26
Exact text from the filing
the Company’s stockholders approved a certificate of amendment (the “Certificate of Amendment”) to the Company’s certificate of incorporation to permit the exculpation of certain of the Company’s officers from liability in specific circumstances.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
KalVista Pharmaceuticals, Inc. shareholders approved Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-09-26 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-09-26
Exact text from the filing
4. Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,203,486 2,450,421 1,385 8,184,921
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
KalVista Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 at the 2023-09-26 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-26
Exact text from the filing
2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024: Shares For Shares Against Shares Abstaining Broker Non-Votes 30,837,741 1,624 848 N/A
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
KalVista Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers at the 2023-09-26 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-09-26
Exact text from the filing
3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,001,348 2,652,134 1,810 8,184,921
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
KalVista Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-09-26 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-26
Exact text from the filing
On September 26, 2023, the Company held its 2023 Annual Meeting of Stockholders (“ Annual Meeting ”) and the following proposals were adopted: 1. Election of two Class II directors, Patrick Treanor and Edward W. Unkart (each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified): Nominees Shares For Shares Against Shares Abstaining Broker Non-Votes Patrick Treanor 15,931,760 6,722,475 1,058 8,184,920 Edward W. Unkart 15,154,122 7,499,378 1,791 8,184,922
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.